Caveat in Chinese trial was the increased symptomatic intracranial hemorrhage risk ...

In a multicenter randomized trial, tenecteplase did not improve vision recovery compared with aspirin when given within 4.5 hours of acute central retinal artery occlusion (CRAO). The ...

Chennai hospital successfully treats a ruptured brain aneurysm using a wrist-based procedure, aiding faster recovery and ...

Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion does not improve vision recovery at 30 days compared with oral aspirin, according to a study ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

When lesion size and location were matched, hemorrhagic stroke produced worse 3 month disability and higher DALYs than ...

Initiation of calcitonin gene-related peptide inhibitors for migraine is linked to a small increased risk for a composite of ...

Healthcare providers are advised to stop using the devices, after a failure to detach was linked with four serious injuries and one death.

Balt’s Squid liquid embolic receives US FDA approval for adjunctive treatment for chronic subdural hematomas: Boston Friday, February 6, 2026, 17:00 Hrs [IST] Balt Inc, a global ...

Central retinal artery occlusion (CRAO) is an ophthalmic emergency that usually leads to sudden and permanent blindness, and ...

Intravenous tenecteplase does not improve vision recovery and is associated with greater incidence of adverse events ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...